medigraphic.com
ISSN 2448-5640 (Print)
Diario Oficial de la Sociedad Mexicana de Cirugía Cardiaca, A.C., y del Colegio Mexicano de Cirugía Cardiovascular y Torácica, A.C.

2016, Number 4

<< Back

Cir Card Mex 2016; 1 (4)

Uso de soporte mecánico circulatorio temporal por más de 30 días en paciente con miocardiopatía dilatada como puente a trasplante cardiaco ortotópico

Maldonado-Alvarado R, Ancheyta-Cervantes LE, Díaz-Quiroz G, García-Ortegón MS, Meléndez-Alambra JF, Rodríguez-Cruz NJ

Language: Spanish
References: 11
Page: 157-159
PDF size: 291.87 Kb.


ABSTRACT

The overall mortality of myocardial infarction was reduced with advances in medical and surgical therapy. However, patients in cardiogenic shock and chronic heart failure continue to have a mortality rate is estimated at 50-60%. Today it is increasingly accessible using ventricular assist devices in patients with refractory cardiogenic shock data to medical management. In developing country is used as an alternative to the lack of access to implantable devices streaming. Then using a temporary circulatory assist device in a patient with terminal heart failure in heart transplant protocol described.


REFERENCES

  1. http://www.thoratec.com/medical-professionals/vad-product-information/thoratec-centrimag.aspx ACCESADO el 23 de Junio del 2016.

  2. Zhang J, Gellman B, Koert A, et al. Computational and experimental evaluationof the fluid dynamics and hemocompatibility of the CentriMag bloodpump. Artif Organs 2006;30(3):168-77.

  3. Miller LW, Pagani FD, Russell SD, et al. Use of a continuous-flow device inpatients awaiting heart transplantation. N Engl J Med 2007; 357(9): 885-96.

  4. Xie A, Phan K, Yan TD. Durability of continuous-flow left ventricular assistdevices: a systematic review. Ann Cardiothhorac Surg 2014; 3(6): 547-56.

  5. Bawiwala MV, Rao V. Left ventricular device as destination therapy: are wethere yet? Curr Opin Cardiol 2009; 24(2): 184-9.

  6. Patel H, Madanieh R, Kosmas CE, Vatti SK, Vittorio TJ. Complications ofContinuous-Flow Mechanical Circulatory Support Devices. Clin Med InsigthsCardiol 2015; 9(Suppl 2):15-2.

  7. Gilotra NA, Stevens GR. Temporary Mechanical Circulatory Support: A Reviewof the Options, Indications, and Outcomes. Clin Med Insights Cardiol2014;8(Suppl 1):75-85.

  8. Kirklin JK, Naftel DC, Pagani FD, Kormos RL. Sixth INTERMACS annualreport: a 10,000-patient database. Heart Lung Traspl 2014;33(6):555-64.

  9. McIlvennan CK, Magid KH, Ambardekar AV, Thompson JS, Matlock DD,Allen LA.Clinical outcomes after continuous-flow left ventricular assist device:a systematic review. Circ Heart Fail 2014; 7(6): 1003-13.

  10. Rossi M, Serraino GF, Jiritano F, Renzulli A. What is the optimal anticoagulationin patients with a left ventricular assist device? Interact CardioVascThorac Surg 2012; 15(4):733-40.

  11. Gilotra NA, Stevens GR. Temporary Mechanical Circulatory Support: A Reviewof the Options, Indications, and Outcomes. Clin Med Insights Cardiol2014;8(Suppl 1):75-85.




2020     |     www.medigraphic.com